Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Debt to Equity (2021)

Barinthus Biotherapeutics (BRNS) has disclosed Debt to Equity for 1 consecutive years, with $0.0 as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Debt to Equity changed N/A year-over-year to $0.0, compared with a TTM value of $0.0 through Dec 2021, changed N/A, and an annual FY2021 reading of $0.0, changed N/A over the prior year.
  • Debt to Equity was $0.0 for Q4 2021 at Barinthus Biotherapeutics.
  • Across five years, Debt to Equity topped out at $0.0 in Q4 2021 and bottomed at $0.0 in Q4 2021.